Protalix BioTherapeutics to Announce Q3 2025 Results on November 13, 2025, Hosts Conference Call and Webcast

jueves, 6 de noviembre de 2025, 6:56 am ET1 min de lectura
PLX--

Protalix BioTherapeutics will announce its Q3 2025 financial and business results on November 13, 2025. The company will host a conference call and webcast at 8:00 a.m. EST to discuss the results and recent developments. Protalix is a biopharmaceutical company focused on developing recombinant therapeutic proteins through its ProCellEx plant cell-based expression system. Its licensed products include taliglucerase alfa for Gaucher disease and Elfabrio for Fabry disease. The company's development pipeline includes PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases.

Protalix BioTherapeutics to Announce Q3 2025 Results on November 13, 2025, Hosts Conference Call and Webcast

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios